KYORIN Pharmaceutical (4569) · RiskRestated
Product Use Restrictions or Discontinuation Due to Unknown Adverse Effects
First written in FY2017. 2 of 3 entries say "Restated". Latest entry: FY2019.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Health Damage and Product Liability Risks Associated with PharmaceuticalsA theme 58 companies write about · 67 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.Full recordFilings, disclosures and news, newest first
- FY2019RestatedAnnual report
「Unknown adverse reactions may lead to restrictions on how the drug is used and, in some cases, discontinuation of its sale.」
The risk of use restrictions or discontinuation of sales due to unknown adverse reactions continues to be disclosed. - FY2018RestatedAnnual report
「Unknown adverse reactions may lead to restrictions on how the drug is used and, in some cases, discontinuation of its sale.」
The risk of use restrictions or discontinuation of sales due to unknown adverse reactions continues to be disclosed. - FY2017First statedAnnual report
「After marketing, an unknown adverse effect may be identified through widespread use, resulting in restrictions on how the pharmaceutical may be used or, in some cases, discontinuation of its sale.」
The Group discloses the risk that unknown adverse effects identified after launch could lead to use restrictions or discontinuation of sales.